


PHARMACEUTICAL 2019

Evolus Inc. Rank 134 of 371









PHARMACEUTICAL 2019

Evolus Inc. Rank 134 of 371



The relative strengths and weaknesses of Evolus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evolus Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Evolus Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is -75%, being 256% points above the market average of -331%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 94,339 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 77,276 |
| Liabilities, Current | 5,276 |
| Liabilities, Non-Current | 0 |
| Other Assets | 229 |
| Other Compr. Net Income | 0 |
| Other Expenses | 11,437 |
| Other Liabilities | 82,184 |
| Other Net Income | 203 |
| Property and Equipment | 0 |
| Research and Development | 6,487 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 29,146 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 171,844 |
| Liabilities | 87,460 |
| Expenses | 47,070 |
| Stockholders Equity | 84,384 |
| Net Income | -46,867 |
| Comprehensive Net Income | -46,867 |
| Economic Capital Ratio | -75% |

